Aker BioMarine ASA expects to submit a new dietary ingredient notification in the US during 2022 for its krill oil fatty acids formulated to deliver targeted eye and brain health benefits by passing through the blood-brain barrier.
The eicapentaenoic acid (EPA) and docosapentaenoic acid (DHA) in ghe firm's Lysoveta formulation are bound by lysophosphatidylcholine (LPC) which allows the fatty acids to pass through the blood-brain barrier via...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?